A MULTICENTER NON-INTERVENTIONAL STUDY EVALUATING THE BENEFIT OF THE COMBINATION OF MABTHERA (RITUXIMAB) WITH STANDARD CHEMOTHERAPEUTIC REGIMENS IN PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA IN HUNGARY
Phase of Trial: Phase IV
Latest Information Update: 02 Jun 2017
Price : $35 *
At a glance
- Drugs Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors Roche
- 30 May 2017 Status changed from active, no longer recruiting to completed.
- 01 Jul 2016 Planned End Date changed from 1 Dec 2016 to 1 Nov 2016.
- 01 Jul 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Nov 2016.